Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C
Table 2
Serum concentrations of the studied parameters in the different studied groups.
Groups, /Parameter
Control, 12
Liver diseases, 73
ASC, 20
Fibrosis, 20
Cirrhosis, 33
AST (U/L)
23.6 ± 2
36 ± 7.5
70 ± 10
69 ± 20
NS
<0.0001
<0.0001
ALT§ (U/L)
26 (23–28)
37.5 (28–50)
100 (40–140)
43 (34–60)
NS
0.015
NS
Bilirubin § (mg/dL)
0.7 (0.6–0.7)
0.75 (0.6–1)
0.9 (0.7–1.1)
2.2 (1.2–2.95)
NS
<0.0001
0.001
Albumin (gm/dL)
3.86 ± 0.27
4 ± 0.22
3.9 ± 0.32
2.8 ± 0.6
NS
0.009
<0.0001
PT %
85 ± 7.3
81 ± 7.3
73.3 ± 6.8
52 ± 13.4
0.019
<0.0001
<0.0001
Glucose (mg/dL)
82 ± 8.7
98 ± 8.5
87 ± 10.7
88 ± 10.7
0.001
NS
0.01
TC (mg/dL)
167 ± 21
176 ± 11.6
177.5 ± 16.2
182 ± 16
NS
NS
NS
TAG (mg/dL)
100 ± 21
123 ± 37
134 ± 33
122 ± 25
NS
NS
NS
HOMA-IR§
1.85 (1.63–2)
2.75 (1.9–3.6)a
4.26 (2.4–5.8)a
4.1 (2.42–7.7)a
NS
NS
0.015
IR (%)
0
8 (40%)
12 (60%)
23 (70%)
TNF-α (pg/mL)§
76.6 (43–141)
616 (535–694)a
205 (157–267)a
280 (205–337)a
0.014
0.002
0.004
Apelin (ng/mL)§
1.11 (0.83–1.42)
2 (1–2.54)a
3 (2.9–3.3)a
3.9 (3.6–4)a
0.001
<0.0001
<0.0001
Apelin-adj (ng/mL)§
0.8 (0.3–1)
0.52 (0.16–0.93)
1.77 (1.17–2)a
2.3 (1.9–2.6)a
0.005
<0.0001
<0.0001
Data are mean ± S.D, § = median (25th and 75th centiles-quartiles). asignificant difference from healthy controls at . AST: Aspartate transaminase; ALT: Alanine Transaminase; PT: Prothrombin time; TC: total cholesterol; TAG: triacylglycerols. for comparison of ASC and fibrosis groups, for comparison of fibrosis and cirrhosis groups, and for comparison of ASC and cirrhosis groups.
